Carregant...
CAR T-cell product performance in haematological malignancies before and after marketing authorisation
Chimeric antigen receptor (CAR) T cells represent a potent new approach to treat haematological malignancies. Two CAR T-cell therapies, tisagenlecleucel and axicabtagene ciloleucel, have been approved in Europe and the USA, as well as several other countries, for the treatment of leukaemia and lymph...
Guardat en:
| Publicat a: | Lancet Oncol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7841982/ https://ncbi.nlm.nih.gov/pubmed/32007196 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(19)30729-6 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|